Literature DB >> 10403352

Determinants of retinopathy progression in type 1 diabetes mellitus.

R A Cohen1, C H Hennekens, W G Christen, A Krolewski, D M Nathan, M J Peterson, F LaMotte, J E Manson.   

Abstract

PURPOSE: To determine the risk factors for retinopathy progression in type 1 (insulin-dependent) diabetes mellitus in a prospective cohort study. SUBJECTS AND METHODS: Subjects were 485 participants in the Sorbinil Retinopathy Trial, a randomized trial of aldose reductase inhibition among patients aged 18 to 56 years with type 1 diabetes mellitus (duration of 1 to 15 years) and no or only mild retinopathy. Retinopathy progression, assessed by seven-field stereoscopic fundus photography, was defined as worsening by two or more levels on a standardized grading scale at the end of follow-up (median, 41 months).
RESULTS: The relative risks for retinopathy progression according to successively greater quintiles of total glycosylated hemoglobin level at baseline, after adjusting for age, diabetes duration, sorbinil assignment, and other variables, were 1.0, 2.0, 1.6, 3.7, and 4.4 (P trend <0.0001). Risk increased with greater baseline diastolic blood pressure: 1.0 for <70 mm Hg, 1.2 for 70 to 79 mm Hg, and 1.8 for > or =80 mm Hg (P for trend = 0.04). Diastolic blood pressure was a significant risk factor for progression in participants with mild baseline retinopathy (P for trend <0.02) but not in those without retinopathy at entry. Systolic blood pressure, by comparison, was not associated with progression. Baseline total cholesterol level was a marginally significant predictor of retinopathy progression when examined as a categorical variable (relative risks for increasing quartiles; 1.0, 1.6, 1.8, 1.9; P for trend = 0.03) but not when it was examined as a continuous variable or when hypercholesterolemic patients were compared with those with normal levels. Furthermore, when cholesterol levels were updated in subsequent visits, it was not a significant predictor of progression, and low density lipoprotein (LDL) cholesterol levels did not predict progression no matter how analyzed. Smoking was not associated with progression of retinopathy.
CONCLUSIONS: Levels of hyperglycemia and diastolic blood pressure predicted progression of retinopathy in type 1 diabetes mellitus. We found only a suggestion of an association between total cholesterol level (but not of LDL cholesterol level) and progression of retinopathy; resolution of this issue will require additional studies with larger sample sizes and longer follow-up.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403352     DOI: 10.1016/s0002-9343(99)00165-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design.

Authors:  Steven Shea; Justin Starren; Ruth S Weinstock; Paul E Knudson; Jeanne Teresi; Douglas Holmes; Walter Palmas; Lesley Field; Robin Goland; Catherine Tuck; George Hripcsak; Linnea Capps; David Liss
Journal:  J Am Med Inform Assoc       Date:  2002 Jan-Feb       Impact factor: 4.497

Review 2.  Obesity and eye diseases.

Authors:  Ning Cheung; Tien Y Wong
Journal:  Surv Ophthalmol       Date:  2007 Mar-Apr       Impact factor: 6.048

3.  Current and future management of diabetic retinopathy: a personalized evidence-based approach.

Authors:  Ryan J Fante; Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Diabetes Manag (Lond)       Date:  2013-11-01

4.  Measurement of retinal function with flash-electroretinography in Chinese patients with hyperlipidemia.

Authors:  Bei Zhang; Qinghua Qiu; Lili Yin; Yuan Yao; Chuan Wang; Xingwei Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-17       Impact factor: 3.117

5.  Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population.

Authors:  Zhale Rajavi; Sare Safi; Mohammad Ali Javadi; Mohsen Azarmina; Siamak Moradian; Morteza Entezari; Ramin Nourinia; Hamid Ahmadieh; Armin Shirvani; Saeid Shahraz; Alireza Ramezani; Mohammad Hossein Dehghan; Mohsen Shahsavari; Masoud Soheilian; Homayoun Nikkhah; Hossein Ziaei; Hasan Behboudi; Fereydoun Farrahi; Khalil Ghasemi Falavarjani; Mohammad Mehdi Parvaresh; Hamid Fesharaki; Majid Abrishami; Nasser Shoeibi; Mansour Rahimi; Alireza Javadzadeh; Reza Karkhaneh; Mohammad Riazi-Esfahani; Masoud Reza Manaviat; Alireza Maleki; Bahareh Kheiri; Faegheh Golbafian
Journal:  J Ophthalmic Vis Res       Date:  2016 Oct-Dec

6.  Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review.

Authors:  Vania Mozetic; Carolina Gomes Freitas; Rachel Riera
Journal:  JMIR Res Protoc       Date:  2017-02-22

7.  Role of lipid-lowering agents in the management of diabetic retinopathy.

Authors:  Estelle Ioannidou; Vasilis-Spyridon Tseriotis; Konstantinos Tziomalos
Journal:  World J Diabetes       Date:  2017-01-15

Review 8.  The Bucherer-Bergs Multicomponent Synthesis of Hydantoins-Excellence in Simplicity.

Authors:  Martin Kalník; Peter Gabko; Maroš Bella; Miroslav Koóš
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

9.  The therapeutic effects of angiotensin-converting enzyme inhibitors in severe non-proliferative diabetic retinopathy.

Authors:  Yong Jae Cha; Sung Jin Kim
Journal:  Korean J Ophthalmol       Date:  2007-03

10.  LDL cholesterol level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes mellitus: A nationwide cohort study.

Authors:  B Rathsman; J Haas; M Persson; J Ludvigsson; A-M Svensson; M Lind; M Andersson Franko; T Nyström
Journal:  J Intern Med       Date:  2020-12-27       Impact factor: 8.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.